Saturday, July 16, 2016 11:08:20 AM
ALSO JUNO MENTIONED
Jul. 15, 2016 8:10 AM ET
About: GlycoMimetics (GLYC), SGEN, Includes: JUNO
William Meyers
Follow (1,085 followers)
Long only, tech, biotech, research analyst
Summary
•Acute Myeloid Leukemia is very difficult to treat successfully.
•Seattle Genetics SGN-CD33A started a Phase 3 trial.
•GlycoMimetics GMI-1271 started Phase 2 trial.
•There are other competitors, but it is unlikely AML will be 100% cured by any one therapy.
http://seekingalpha.com/article/3988622-aml-therapies-seattle-genetics-vs-glycomimetics?ifp=0&app=1
FEATURED Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • Apr 22, 2024 8:49 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM